Research study Program year 2025 Source: CMS Open Payments

Ocrelizumab PPMS High Dose Study

Research payments

$8,467,911

653 payments

Through program year 2025, $8,467,911 in research payments was reported against Ocrelizumab PPMS High Dose Study, across 653 payments.

Paid by (largest first): Genentech, Inc.; F. Hoffmann-La Roche AG
ClinicalTrials.gov: No trial number was reported for this study

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,474,309	131
2024	Research	$2,247,456	153
2023	Research	$1,452,706	151
2022	Research	$2,438,466	168
2021	Research	$854,974	50

Breakdown

Who paid Research payments · program years 2021–2025

Genentech, Inc. $6,209,444 637 payments
F. Hoffmann-La Roche AG $2,258,467 16 payments

Who received the money Research payments · program years 2021–2025

Langley Porter Psychiatric Hospital Teaching hospital · CA $2,254,956 12 payments
Cleveland Clinic Hospital Teaching hospital · OH $851,960 23 payments
Hackensack University Medical Center Teaching hospital · NJ $764,478 14 payments
Board Of Trustees Of The Leland Stanford Junior University Organisation paid for research $325,662 32 payments
The University Of Texas Southwestern Medical Center Organisation paid for research $282,167 14 payments
Ms Neuromuscular Center Of Excellence LLC Organisation paid for research $223,732 37 payments
Uci Medical Center Teaching hospital · CA $222,331 27 payments
Washington Univ School Of Medicine Center For Clinical Studies Organisation paid for research $202,957 25 payments
Michigan Institute For Neurologica Disorders Glendale Neurological Associates Organisation paid for research $187,105 39 payments
Neurology Clinic Pc Organisation paid for research $182,492 15 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

6 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.